Study finds remdesivir, hydroxychloroquine have ‘little’ impact on mortality in COVID-19 patients

/ / News

A clinical trial conducted by the World Health Organization found that Gilead Sciences Inc.’s remdesivir, hydroxychloroquine, AbbVie’s lopinavir/ritonavir and interferon did not impact mortality among hospitalized COVID-19 patients. The study was first reported by the Financial Times on Thursday. In a preprint, which is medical research that has not been peer-reviewed, researchers said that the four antiviral drugs had “little or no effect” on overall mortality, ventilation, and length of hospital stay among the 11,330 patients participating in the study. The Food and Drug Administration has authorized remdesivir as a COVID-19 treatment, based on a clinical study conducted in the U.S. that found the drug could reduce recovery times. It had also granted an emergency use authorization to hydroxychloroquine as a COVID-19 treatment although that EUA was rescinded this summer. So far this year, Gilead’s stock is down 3.1%, shares of AbbVie have tumbled 3.7%, and the S&P 500 is up 7.8%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.